Author

Suzanne Gross

New York University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Dimitris G. PlacantonakisiD· 2 shared Adler Guerrero· 1 shared Akiko KoideiD· 1 shared Albert Jiang· 1 shared Alex Donovan· 1 shared Alexis D. CorradoiD· 1 shared Andrea H. BrandiD· 1 shared Andrea Leonard· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Dimitris G. PlacantonakisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Purinergic signaling promotes gliomagenesis through nuclear calcium transients

Shuai Wang, Jenna Richter, Claire Kim, Rebecca Ronnen, Julia Cai, Yunfei Song, Sara Haddock, Mark B. Stoessel, Hannah Dada, Suzanne Gross, Adler Guerrero, Theodoris Karnavas, Gabriele Stephan, Greg Belizaire, Luke J. Bonanni, , Dimitris G. Placantonakis

This study identifies purinergic signaling via P2RY1 receptors and nuclear calcium transients as a driver of glioblastoma tumorigenesis, with therapeutic potential through P2RY1 inhibition.

bioRxiv · May 15, 2026 · PreprintCancer Biology

Engineering Antibody-Drug Conjugates targeting an Adhesion GPCR, CD97

Takamitsu Hattori, Michelle Y. Wang, Alexis D. Corrado, Suzanne Gross, Michelle Fang, Injin Bang, Nainita Roy, Iryna Berezniuk, Hayley Donaldson, Karenna J. Groff, Niklas Ravn-Boess, Akiko Koide, Dimitris G. Placantonakis, Christopher Y. Park, Shohei Koide

This study develops antibody-drug conjugates targeting CD97, an aGPCR overexpressed in cancer, showing efficacy against AML and GBM cells with minimal off-target toxicity.

Proceedings of the National Academy of Sciences · Sep 30, 2025Peer-reviewedBiochemistry